Abstract:In this study, we show that the administration of a senolytic drug cocktail of dasatinib and quercetin reverses age‐related increases in senescence and inflammation in the adipose tissue. This drug treatment also improves metabolic function in old age. Results from this study have implications for developing new drugs to treat metabolic dysfunction and associated diseases such as diabetes. Aging results in an elevated burden of senescent cells, senescence‐associated secretory phenotype (SASP), and tissue infiltration of immune cells contributing to chronic low‐grade inflammation and a host of age‐related diseases. Recent evidence suggests that the clearance of senescent cells alleviates chronic inflammation and its associated dysfunction and diseases. However, the effect of this intervention on metabolic function in old age remains poorly understood. Here, we demonstrate that dasatinib and quercetin (D&Q) have senolytic effects, reducing age‐related increase in senescence‐associated β‐galactosidase, expression of p16 and p21 gene and P16 protein in perigonadal white adipose tissue (pgWAT; all p ≤ 0.04). This treatment also suppressed age‐related increase in the expression of a subset of pro‐inflammatory SASP genes (mcp1, tnf‐α, il‐1α, il‐1β, il‐6, cxcl2, and cxcl10), crown‐like structures, abundance of T cells and macrophages in pgWAT (all p ≤ 0.04). In the liver and skeletal muscle, we did not find a robust effect of D&Q on senescence and inflammatory SASP markers. Although we did not observe an age‐related difference in glucose tolerance, D&Q treatment improved fasting blood glucose (p = 0.001) and glucose tolerance (p = 0.007) in old mice that was concomitant with lower hepatic gluconeogenesis. Additionally, D&Q improved insulin‐stimulated suppression of plasma NEFAs (p = 0.01), reduced fed and fasted plasma triglycerides (both p ≤ 0.04), and improved systemic lipid tolerance (p = 0.006). Collectively, results from this study suggest that D&Q attenuates adipose tissue inflammation and improves systemic metabolic function in old age. These findings have implications for the development of therapeutic agents to combat metabolic dysfunction and diseases in old age.

Senolytics Cocktail Dasatinib and Quercetin Alleviate Human Umbilical Vein Endothelial Cell Senescence via the TRAF6-MAPK-NF-κB Axis in a YTHDF2-Dependent Manner

Senolytics prevent caveolar CaV3.2‐RyR axis malfunction in old vascular smooth muscle

Combined dasatinib and quercetin treatment contributes to skin rejuvenation through selective elimination of senescent cells in vitro and in vivo

Senolytics and Senomorphics Targeting p38MAPK/NF-κB Pathway Protect Endothelial Cells from Oxidative Stress-Mediated Premature Senescence

Senolytic drugs, dasatinib and quercetin, attenuate adipose tissue inflammation, and ameliorate metabolic function in old age

ORALLY ACTIVE, CLINICALLY TRANSLATABLE SENOLYTICS RESTORE Α-KLOTHO IN MICE AND HUMANS

RNA m6A methylation regulatory mechanism of resveratrol in premature senescence cells

H2O2 Down-Regulates SIRT7's Protective Role of Endothelial Premature Dysfunction Via Microrna-335-5p.

Senescent Cell Depletion Through Targeting BCL-Family Proteins and Mitochondria

Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

Abstract 100: Omics Strategies To Identify Senescent Cells Mediating Extracellular Matrix Remodeling During Vascular Disease

Inhibition of S-adenosylhomocysteine Hydrolase Induces Endothelial Senescence Via Htert Downregulation.

Epigenetic Modulation of Drp1-mediated Mitochondrial Fission by Inhibition of S-adenosylhomocysteine Hydrolase Promotes Vascular Senescence and Atherosclerosis

Tetrahydroxy Stilbene Glycoside Attenuates Endothelial Cell Premature Senescence Induced by H2O2 Through the Microrna-34A/sirt1 Pathway

Dihydroartemisinin eliminates senescent cells by promoting autophagy‐dependent ferroptosis via AMPK/mTOR signaling pathway

Dietary Nucleotides Retard Oxidative Stress-Induced Senescence of Human Umbilical Vein Endothelial Cells

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Anti-senescent effects of long non-coding RNA H19 on human dermal fibroblast cells through impairing microRNA-296-5p-dependent inhibition of IGF2

Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence

Hyperglycemia Promotes Endothelial Cell Senescence through AQR/PLAU Signaling Axis

Heme oxygenase-1 ameliorates oxidative stress-induced endothelial senescence via regulating endothelial nitric oxide synthase activation and coupling